Amgen and Allergan plc. said they have submitted a Biologics License Application to FDA for ABP 980, a biosimilar candidate to Herceptin (trastuzumab).
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe